Alkermes (ALKS) Commences ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. SPY
2. USO
3. IONQ
4. QCOM
5. IONS
6. ACN
7. AZN
8. ROIV
9. AAPL
10. HOOD

Go back to Alkermes (ALKS) Commences ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer
ALKERMES (NASDAQ: ALKS) Delayed: 45.49 -0.61 (1.32%)
Previous Close $46.10    52 Week High $80.71 
Open $45.20    52 Week Low $27.14 
Day High $46.53    P/E 349.92 
Day Low $44.63    EPS $0.13 
Volume 1,355,833